SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Chinese pharmaceutical giant WuXi AppTec (SS:603259) expects its first-half net profit to more than double, driven by soaring demand for its contract research and manufacturing services. The company announced on Thursday that net profit attributable for the six months ending June 30 is projected to jump 101.9% year-over-year, reaching 8.56 billion yuan (approximately $1.19 billion). This surge includes a significant one-time gain from the partial divestment of its subsidiary, WuXi XDC Cayman.
Excluding one-off items, adjusted net profit is forecast to rise 44.4% to 6.31 billion yuan, underscoring strong performance in its integrated CRDMO (Contract Research, Development, and Manufacturing Organization) business model. The firm said that increasing global demand for end-to-end drug development solutions has been a key growth driver.
Total revenue for the first half of 2025 is expected to grow 20.6% year-over-year, reaching approximately 20.8 billion yuan. Revenue from core operations alone rose by 24.2%, reflecting enhanced operational efficiency and expanded manufacturing capacity.
WuXi AppTec’s continued investment in innovation, infrastructure, and client-centric services is positioning the company as a global leader in pharmaceutical outsourcing. With the biotech and pharmaceutical sectors increasingly relying on external partners to accelerate drug development pipelines, WuXi AppTec appears well-placed to capitalize on this structural shift.
The company’s impressive growth trajectory reinforces confidence in its CRDMO strategy, which offers integrated solutions across research, development, and manufacturing phases. As global demand for efficient and scalable pharmaceutical services rises, WuXi AppTec’s performance signals strong momentum heading into the second half of the year.
